Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2004

View Archived Issues

Vernalis highlights interim pipeline progress

Pain Therapeutics reports 2003 progress

Millennium highlights year-end and Q4 2003 progress

Connetics makes substantial progress during Q4 2003

Biological effects and safety of MDX-H210 plus filgrastim in advanced breast cancer

Three series of hypolipidemic agents presented by Aventis Pharma

New liver-selective GR antagonists prepared and tested at Abbott

Akzo Nobel describes new CB1 agonists with analgesic activity

Novel histamine H3 antagonists in early development at Schering-Plough

Novel cathepsin inhibitors described by AxyS researchers

Acadia claims novel 5-HT2A inhibitors with potential as antipsychotics

Novel muscarinic M3 antagonists identified at Almirall Prodesfarma

Biovitrum claims 5-HT6 modulators for obesity and other disorders

IP3R3 involved in peritoneal metastasis of gastric cancers

JNJ-5207787, a novel neuropeptide Y Y2 receptor antagonist, may be a potent pharmacological tool

Novel selective and orally active oxytocin receptor antagonist for the prevention of preterm labor

Vertex and Novartis amend protein kinase collaboration agreement

NeuroSearch plans two phase II studies of NS-1209

Sanofi-Synthelabo acquires Taisho's stake in Japanese joint venture

Phase I ThermoDox protocol amendments allowed

Orphan drug status sought for Myodur

ABX-PTH enters phase I trial in patients with secondary hyperparathyroidism

Cytos to supply Alzheimer's Immunodrug to Novartis

Phase II trials of extended-release Sonata cleared to commence

IND filing to study Antegren for rheumatoid arthritis

New Imitrex available for rapid disintegration in stomach

Homspera shows potential utility for Hong Kong virus in mouse study

Gilead reports long-term effects of Viread in naive HIV-infected patients

Anti-GPIIb/IIIa therapy enhances the effects of intraarterial TNK-tPA in stroke